UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model

Objectives In 2002, the UK's National Institute for Health and Care Excellence concluded that the multiple sclerosis (MS) disease modifying therapies; interferon-β and glatiramer acetate, were not cost effective over the short term but recognised that reducing disability over the longer term mi...

Full description

Saved in:
Bibliographic Details
Main Authors: Jacqueline Palace, Martin Duddy, Thomas Bregenzer, Mike Boggild, Joel Oger, Helen Tremlett, Charles Dobson, Fheng Zhu
Format: Article
Language:English
Published: BMJ Publishing Group 2014-01-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/4/1/e004073.full
Tags: Add Tag
No Tags, Be the first to tag this record!